Free Trial
CVE:PTF

Pender Growth Fund (PTF) Stock Price, News & Analysis

Pender Growth Fund logo
C$13.56 +0.02 (+0.15%)
As of 07/3/2025 02:00 PM Eastern

About Pender Growth Fund Stock (CVE:PTF)

Key Stats

Today's Range
C$13.56
C$14.40
50-Day Range
C$9.85
C$14.59
52-Week Range
C$9.29
C$14.99
Volume
1,000 shs
Average Volume
2,960 shs
Market Capitalization
C$98.32 million
P/E Ratio
2.19
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pender Growth Fund and its competitors with MarketBeat's FREE daily newsletter.

PTF Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Headlines

PTF Stock Analysis - Frequently Asked Questions

Pender Growth Fund's stock was trading at C$11.19 at the beginning of the year. Since then, PTF shares have increased by 21.2% and is now trading at C$13.56.

Shares of PTF stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pender Growth Fund investors own include Armata Pharmaceuticals (ARMP), BioCardia (BCDA), Bristol Myers Squibb (BMY), Range Cancer Therapeutics ETF (CNCR), Inovio Pharmaceuticals (INO), Insight Select Income Fund (INSI) and Protalix BioTherapeutics (PLX).

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Asset Management
Sub-Industry
N/A
Current Symbol
CVE:PTF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
2.19
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$44.92 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$49.38 million
Cash Flow
C$1.62 per share
Price / Cash Flow
8.35
Book Value
C$15.08 per share
Price / Book
0.90

Miscellaneous

Free Float
N/A
Market Cap
C$98.32 million
Optionable
Not Optionable
Beta
0.56
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (CVE:PTF) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners